• Contact us
Saturday, November 14, 2026
Register
Login
European Press
ADVERTISEMENT Handpicked deals on Amazon Discover useful products selected for our readers. Explore deals ›
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video
No Result
View All Result
European Press
No Result
View All Result

FDA approves first-of-its-kind stroke prevention pill that cuts risk of recurrence

14 November 2026
in Health
Reading Time: 3 mins read
A A
FDA approves first-of-its-kind stroke prevention pill that cuts risk of recurrence
ShareShareShareShareShare


NEWYou can now listen to Fox News articles!
The FDA has approved Sunharbo (asundexian) to reduce the risks of a recurring stroke in some adults.The medication is taken as one 50-mg pill each day, along with standard blood-clot-preventing medicine, such as aspirin.It is designed to lower the risk of another stroke in adults who recently had a stroke caused by a blood clot (not a heart-related clot) or a mini-stroke (transient ischemic attack, or TIA), which is a temporary interruption of blood flow to the brain, according to the FDA release.HEALTHY RUNNER SUFFERS SUDDEN STROKE AT 27 AS DOCTORS DISCOVER POSSIBLE CAUSESunharbo is the first medication of its kind to block a specific protein in the blood (factor XIa) that helps blood clots form.”This blocks a very specific protein that’s part of the cascade of blood clotting,” Dr. Richard Kovacs, a cardiologist at Indiana University School of Medicine and chief medical officer of the American College of Cardiology, told Fox News Digital. The FDA has approved Sunharbo (asundexian) to reduce the risks of a recurring stroke in some adults. (iStock)Approval followed a phase 3 randomized trial involving 12,327 patients across 37 countries, all of whom had a recent non-cardioembolic ischemic stroke or high-risk TIA.Among those who took 50 mg of asundexian orally once daily plus antiplatelet therapy for a period of 14.2 months, there was a 26% relative reduction in ischemic stroke compared to groups who took a placebo along with antiplatelet therapy.COMMON HEART PILL UNDER SCRUTINY FOR OLDER PATIENTS AS STUDY WEIGHS RISKS OF STOPPINGAlthough there was not a significant overall increase in major bleeding, the risk of that side effect was higher in certain subgroups. However, gastrointestinal bleeding was more common with asundexian, and major bleeding was increased among patients older than 75 during the first 90 days.Patients who took asundexian also had a lower risk of stroke, heart attack or death compared with those who received a placebo. The medication is designed to lower the risk of another stroke in adults who recently had a stroke caused by a blood clot or a mini-stroke (transient ischemic attack, or TIA), which is a temporary interruption of blood flow to the brain. (iStock)About 6.6% of patients taking asundexian experienced a stroke, compared with 8.8% in the placebo group.”So it doesn’t completely eliminate the risk of a second stroke,” Kovacs said.EVEN OCCASIONAL MARIJUANA USE LINKED TO HIGHER STROKE RISK, STUDY FINDSThe risk of death from heart-related causes, heart attack or stroke was also lower among patients taking asundexian (9.2% versus 11.1%).Similarly, 10.5% of patients taking the medication experienced death from any cause, compared with 12.3% of those receiving a placebo.”This drug is not for patients who have had strokes due to atrial fibrillation or due to a valve problem in their heart.” The findings were published in The New England Journal of Medicine on Nov. 9.The trial, which was funded by Bayer, the manufacturer of asundexian, had several limitations.CLICK HERE FOR MORE HEALTH STORIESBecause patients were treated for an average of about 14 months, long-term safety and effectiveness of the medication are unclear.The study also excluded patients with certain heart conditions and those with more severe strokes. About 6.6% of patients taking asundexian experienced a stroke, compared with 8.8% in the placebo group. (iStock)”Importantly, this drug is not for patients who have had strokes due to atrial fibrillation or due to a valve problem in their heart,” Kovacs said.Longer-term studies are needed to identify safety and effectiveness among older patients, underrepresented populations and patients with greater stroke severity, the researchers noted.CLICK HERE TO DOWNLOAD THE FOX NEWS APPKovacs emphasized that patients should discuss the medication with their care team soon after a stroke.”In the clinical trial that approved this drug, this drug was given very soon after the stroke – within 72 hours,” he said. “So it’s important to have that conversation about whether this is a drug for the patient early on, often in the hospital.” The medication is taken as one 50-mg pill each day, along with standard blood-clot-preventing medicine, such as aspirin. (iStock)Medication is only one part of preventing another stroke, the cardiologist emphasized.”The cause of the stroke in many of these patients was atherosclerosis,” he said, describing the condition as “plaque buildup that can cause circulation problems and the lack of blood flow to the brain.”CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER”So it’s important for any stroke patient to do all the other things that you can do in addition to this medicine to prevent a second stroke – like stopping smoking, keeping your cholesterol low, eating healthy, and most importantly, getting exercise.”TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZMore than 795,000 people in the U.S. have a stroke each year, including about 185,000 who have had one before, according to the CDC.About one in four stroke survivors experiences another within five years. Melissa Rudy is senior health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com.

Credit: Source link

Previous Post

I’m A Celebrity star Joanna Page reveals secret heartache that could see her struggle in the jungle

Next Post

Woman ditches 10-year marriage for pet pig — ‘This is my dream and I’m finally living it’

Recommended

Josh Hart admits he’s ‘not in a good head space’as his Knicks struggles mount

Josh Hart admits he’s ‘not in a good head space’as his Knicks struggles mount

14 November 2026

INDIANAPOLIS — Josh Hart’s issues aren’t exclusive to his shot. The Knicks veteran said he’s mentally struggling to start a...

Safeguarding Savings: Deposit Insurance and Financial Literacy

Safeguarding Savings: Deposit Insurance and Financial Literacy

14 November 2026

Saving money is an important step toward financial security. But saving alone is not enough. People also need to understand how...

SpaceX Starship landing livestream: Watch the catch attempt live

SpaceX Starship landing livestream: Watch the catch attempt live

14 November 2026

SpaceX is attempting rocketry history on Saturday, and you can watch it from the comfort of your home.Elon Musk's spacefaring...

Woman ditches 10-year marriage for pet pig — ‘This is my dream and I’m finally living it’

Woman ditches 10-year marriage for pet pig — ‘This is my dream and I’m finally living it’

14 November 2026

After a 10-year marriage, Gayla Thompson got a fresh start — in a pigsty. Freshly divorced, the 33-year-old Nashville native...

Datenschutzinformationen

Disclaimer  Privacy Policy – EU  Imprint 

Join European Press

Contact us

What’s New Here!

  • Josh Hart admits he’s ‘not in a good head space’as his Knicks struggles mount
  • Safeguarding Savings: Deposit Insurance and Financial Literacy
  • SpaceX Starship landing livestream: Watch the catch attempt live
  • Woman ditches 10-year marriage for pet pig — ‘This is my dream and I’m finally living it’

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

© 2026 European Press. All rights reserved.

European Press
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video

© 2026 European Press. All rights reserved.

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?